Pallas Capital Advisors LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History
Pallas Capital Advisors LLC
- $2.43 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding APLS
# of Institutions
289Shares Held
129MCall Options Held
1.01MPut Options Held
787K-
Avoro Capital Advisors LLC New York, NY12.2MShares$292 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$284 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$243 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$230 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$215 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.63B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...